Company intelligence / Profile preview

BIOCORP

Issoire, Auvergne-Rhône-Alpes, Francebiocorplab.com ↗

Ownership: Private
Employees: ~129
Development stage: Other

Overview

BIOCORP specializes in the design, development, and manufacturing of innovative connected medical devices for drug delivery, with a particular focus on diabetes. Its flagship product Mallya is a smart sensor that attaches to insulin pens to track and transmit injection data. The company has demonstrated commercial traction and was acquired by Novo Nordisk in 2023.

Therapeutic areas: Endocrinology
Modalities: DeviceConnected device (digital health)
Industry: Therapeutic Medical Devices

Partnerships

Novo Nordisk (commercial partner since at least 2021; now parent)potential partnerships with pharmaceutical companies for drug-device integration

Beyond the preview

Go deeper on BIOCORP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIOCORP.

Explore the full profile